News

Immunocore Secures $320 Million (£205 million) in Europe’s Largest Pri


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Immunocore Secures $320 Million (£205 million) in Europe’s Largest Private Life Sciences Financing

 

Date: 17/07/2015

 

Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round.

The oversubscribed round includes new investors, Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and RTW Investments, as well as a number of new and existing investors in Immunocore.

The proceeds will enable Immunocore to further accelerate its pipeline of ImmTACs (Immune mobilising mTCR Against Cancer). ImmTACs are a new class of bispecific biologics which have the potential to treat a broad range of solid tumours either as monotherapies or in combination with other therapies to create best in class treatment regimes. In addition to delivering on its well-established partnerships, Immunocore will focus, in particular, on progressing its lead proprietary programme, IMCgp100, which produced positive Phase I/IIa trial data in April 2015 in patients with advanced metastatic cutaneous and ocular melanoma.

Dr. Eliot Forster, Chief Executive Officer of Immunocore, commented on the financing round: “We are delighted by the interest we have received in this financing round which was significantly oversubscribed.

For more click here

Source: OBN

© Catalyst Innovation Portal 2019